An Overview of siRNA Delivery Strategies for Urological Cancers

被引:8
作者
Halib, Nadia [1 ]
Pavan, Nicola [2 ]
Trombetta, Carlo [2 ]
Dapas, Barbara [3 ]
Farra, Rossella [3 ]
Scaggiante, Bruna [3 ]
Grassi, Mario [4 ]
Grassi, Gabriele [3 ]
机构
[1] Univ Sains Islam Malaysia, Fac Dent, Dept Basic Sci & Oral Biol, Kuala Lumpur 55100, Malaysia
[2] Univ Trieste, Dept Med Surg & Hlth Sci, Urol Clin, I-34149 Trieste, Italy
[3] Trieste Univ, Cattinara Univ Hosp, Dept Life Sci, Str Fiume 447, I-34149 Trieste, Italy
[4] Trieste Univ, Dept Engn & Architecture, Via Valerio 6, I-34127 Trieste, Italy
关键词
bladder cancer; prostate cancer; renal cancer; siRNA; delivery; PROSTATE-CANCER; IN-VITRO; BLADDER-CANCER; DRUG-DELIVERY; SIOG GUIDELINES; ULTRASONIC DRUG; KINASE; NANOPARTICLES; EXPRESSION; CARCINOMA;
D O I
10.3390/pharmaceutics14040718
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The treatment of urological cancers has been significantly improved in recent years. However, for the advanced stages of these cancers and/or for those developing resistance, novel therapeutic options need to be developed. Among the innovative strategies, the use of small interfering RNA (siRNA) seems to be of great therapeutic interest. siRNAs are double-stranded RNA molecules which can specifically target virtually any mRNA of pathological genes. For this reason, siRNAs have a great therapeutic potential for human diseases including urological cancers. However, the fragile nature of siRNAs in the biological environment imposes the development of appropriate delivery systems to protect them. Thus, ensuring siRNA reaches its deep tissue target while maintaining structural and functional integrity represents one of the major challenges. To reach this goal, siRNA-based therapies require the development of fine, tailor-made delivery systems. Polymeric nanoparticles, lipid nanoparticles, nanobubbles and magnetic nanoparticles are among nano-delivery systems studied recently to meet this demand. In this review, after an introduction about the main features of urological tumors, we describe siRNA characteristics together with representative delivery systems developed for urology applications; the examples reported are subdivided on the basis of the different delivery materials and on the different urological cancers.
引用
收藏
页数:27
相关论文
共 50 条
  • [21] Pharmacometabolomics Applied to Personalized Medicine in Urological Cancers
    Amaro, Filipa
    Carvalho, Marcia
    Bastos, Maria de Lourdes
    de Pinho, Paula Guedes
    Pinto, Joana
    PHARMACEUTICALS, 2022, 15 (03)
  • [22] A review for the impacts of circadian disturbance on urological cancers
    Li, Tao
    Jiang, Yiting
    Bai, Yunjin
    Jiang, Kehua
    Du, Guangshi
    Chen, Peng
    Luo, Chao
    Li, Lei
    Qiao, Jun
    Shen, Jun
    SLEEP AND BIOLOGICAL RHYTHMS, 2024, 22 (02) : 163 - 180
  • [23] Urinary microbiome and urological cancers: a mini review
    Randazzo, Gianmarco
    Bovolenta, Eleonora
    Ceccato, Tommaso
    Reitano, Giuseppe
    Betto, Giovanni
    Novara, Giacomo
    Iafrate, Massimo
    Morlacco, Alessandro
    Dal Moro, Fabrizio
    Zattoni, Fabio
    FRONTIERS IN UROLOGY, 2024, 4
  • [24] Matrix Systems for siRNA Delivery
    Naeye, B.
    Raemdonck, K.
    Remaut, K.
    Demeester, J.
    De Smedt, S. C.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2012, 12 (02) : 89 - 96
  • [25] Nanoplatforms for Delivery of siRNA to the Eye
    Kataki, Manjir Sarma
    Kakoti, Bibhuti Bhusan
    Jameson, Melanie
    Solanki, Aum
    Hirani, Anjali
    Pathak, Yashwant
    CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (31) : 4587 - 4593
  • [26] Diagnostic and prognostic biomarkers of common urological cancers based on aberrant DNA methylation
    Peng, Ding
    Ge, Guangzhe
    Xu, Zhengzheng
    Ma, Qin
    Shi, Yue
    Zhou, Yuanyuan
    Gong, Yanqing
    Xiong, Gengyan
    Zhang, Cuijian
    He, Shiming
    He, Zhisong
    Li, Xuesong
    Ci, Weimin
    Zhou, Liqun
    EPIGENOMICS, 2018, 10 (09) : 1189 - 1199
  • [27] Mesenchymal stem cells and their extracellular vesicles in urological cancers: Prostate, bladder, and kidney
    Saadh, Mohamed J.
    Alhuthali, Hayaa M.
    Anibal, Oblitas Gonzales
    Asenjo-Alarcon, Jose Ander
    Younus, Dhuha Ghassan
    Alhili, Ahmed
    Adhab, Zainab Hussein
    Alsalmi, Ohud
    Gharib, Amal F.
    Pecho, Renzon Daniel Cosme
    Akhavan-Sigari, Reza
    CELL BIOLOGY INTERNATIONAL, 2024, 48 (01) : 3 - 19
  • [28] Strategies and advances in nanomedicine for targeted siRNA delivery
    Nimesh, Surendra
    Gupta, Nidhi
    Chandra, Ramesh
    NANOMEDICINE, 2011, 6 (04) : 729 - 746
  • [29] GENE-THERAPY IN UROLOGICAL ONCOLOGY - PRINCIPLES, STRATEGIES AND POTENTIAL
    BREWSTER, SF
    SIMONS, JW
    EUROPEAN UROLOGY, 1994, 25 (03) : 177 - 182
  • [30] Recent Advances in siRNA Delivery Systems for Prostate Cancer Therapy
    Aghamiri, Shahin
    Raee, Pourya
    Shahmohamadnejad, Shiva
    Shabani, Sasan
    Ghorbani, Jaber
    Sameni, Marzieh
    Ebrahimi, Mohammad Taha
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2022, 23 (04) : 579 - 593